THE EFFECT OF METFORMIN COMBINED WITH SITAGLIPTIN ON TYPE 2 DIABETES MELLITUS AND THE ISLETS FUNCTION

Objective: To explore the e f fect of metformin combined with sitagliptin in the treatment of type 2 diabetes mellitus and its effect on the islets fitnction. Methods: A total of 84 cases of type 2 diabetes diagnosed in our hospital from December 2017 to December 2018 were selected for the present study. The patients were randomly divided into three groups. The sitagliptin group (n=28, recorded as group A) was only treated with sitagliptin, while patients in group B (n= )were only treated with metformin. Patients in the combined group (n=28, recorded as group C) were treated with both sitagliptin and metformin. The patients were randomly divided into three groups. Blood glucose control, islet beta cell function [FBG (fasting blood glucose), 2-hour postprandial blood glucose (2hPG), HbAlc, HOMA-IR, HOMA-beta 1, blood lipid, blood pressure, and metabolism (IG, TC, LDL-C, BIM, SBP, DBP) were compared among the three groups. Results: The levels of FBG, 2hPG, HbA1c and HOMA-IR in the three groups decreased significantly (P<0.05), while the levels of HOMA-beta in the three groups increased significantly (P<0.05). However, the differences between the indexes between groups A and B were not significant, while the levels of FBG, 2hPG and HbA1c in group C decreased significantly (P<0.05). While the level of HOMA-beta increased significantly (P<0.05), there was no significant difference in HOMA-IR among the three groups after treatment (P>0.05). Moreover, the TG, TC, LDL-C, SBP and DBP values of the three groups were significantly lower after treatment (P<0.05); however, no significant differences in TG, TC, LDL-C, SBP and DBP values were observed between groups A and B, while the TG, TC, LDL-C, SBP and DBP values of group C after treatment were significantly lower than those of the other two groups (P<0.05). While BMI level in group A was not significantly different before and after treatment (P<0.05), there was a significant decrease in groups B and C before treatment (P<0.05), and between groups B and C before and after treatment (P<0.05). Conclusion: Sitagliptin combined with metformin is beneficial in the treatment of type 2 diabetes and to the improvement of islet function, patient quality of life and the reduction of energy and financial costs associated with type 2 diabetes.